We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-12.43%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$367M
AUM Growth
-$16.9M
Cap. Flow
+$54.7M
Cap. Flow %
14.9%
Top 10 Hldgs %
47.4%
Holding
97
New
3
Increased
38
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$25.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.2M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.15M
4
ACET icon
Adicet Bio
ACET
+$3.02M
5
ALEC icon
Alector
ALEC
+$2.59M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.3M
2
LONA
LeonaBio Inc
LONA
+$2.17M
3
COGT icon
Cogent Biosciences
COGT
+$1.67M
4
IMCR icon
Immunocore
IMCR
+$1.61M
5
NTUS
Natus Medical Inc
NTUS
+$1.49M

Sector Composition

Rank Sector Weight
1 Healthcare 80.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REUN
51
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$1.6M 0.44%
380,828
-57,434
-13% -$287K
AUTL
52
Autolus Therapeutics
AUTL
$516M
$1.4M 0.38%
496,150
– –
PRDS
53
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.39M 0.38%
451,105
+29,948
+7% +$183K
NGM
54
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.38M 0.38%
107,653
– –
VKTX icon
55
Viking Therapeutics
VKTX
$3.88B
$1.34M 0.36%
462,400
+15,000
+3% +$37.1K
MREO
56
Mereo BioPharma
MREO
$52.4M
$1.23M 0.33%
1,096,513
-120,100
-10% -$93.1K
WVE icon
57
Wave Life Sciences
WVE
$1.16B
$1.21M 0.33%
372,361
-17,800
-5% -$34.2K
RGLS
58
DELISTED
Regulus Therapeutics
RGLS
$1.15M 0.31%
555,555
-1
-0% -$2
KROS icon
59
Keros Therapeutics
KROS
$201M
$1.08M 0.29%
+39,000
New +$1.71M
LITS
60
Lite Strategy Inc
LITS
$32.8M
$1.07M 0.29%
88,357
– –
STIM icon
61
Neuronetics
STIM
$155M
$1.01M 0.27%
313,717
– –
BWAY
62
Brainsway
BWAY
$635M
$966K 0.26%
400,000
– –
RDUS
63
DELISTED
Radius Health, Inc.
RDUS
$953K 0.26%
91,935
-100,043
-52% -$744K
NXTC icon
64
NextCure
NXTC
$23M
$882K 0.24%
15,641
– –
SCYX icon
65
SCYNEXIS
SCYX
$53.4M
$845K 0.23%
56,812
+41,657
+275% +$802K
CMPS
66
Compass Pathways
CMPS
$1.56B
$810K 0.22%
74,890
– –
BDTX icon
67
Black Diamond Therapeutics
BDTX
$101M
$771K 0.21%
313,600
– –
GNFT
68
DELISTED
Genfit
GNFT
$605K 0.16%
187,940
– –
ADAP
69
DELISTED
Adaptimmune Therapeutics
ADAP
$597K 0.16%
351,064
– –
MGNX icon
70
MacroGenics
MGNX
$251M
$566K 0.15%
192,000
– –
GHRS icon
71
GH Research
GHRS
$2B
$549K 0.15%
55,000
– –
CMPX icon
72
Compass Therapeutics
CMPX
$355M
$525K 0.14%
198,094
+2,003
+1% +$4.35K
THRX
73
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$453K 0.12%
81,899
+1,775
+2% +$14.7K
VERO
74
DELISTED
Venus Concept
VERO
$449K 0.12%
5,868
– –
RIGL icon
75
Rigel Pharmaceuticals
RIGL
$722M
$441K 0.12%
39,007
-50,603
-56% -$1.02M
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, DAFNA Capital Management held 97 positions worth $367M, down 4.4% from $384M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $54.7M of net new capital in Q2 2022, opening 3 new positions and adding to 38 existing holdings. Its largest new stake was Keros Therapeutics: 39,000 shares worth $1.08M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Karuna Therapeutics, Inc. Common Stock, an estimated $2.3M trimmed.

  • DAFNA Capital Management's largest Q2 2022 buy was Keros Therapeutics: 39,000 shares worth $1.08M.
  • DAFNA Capital Management added most to State Street SPDR S&P Biotech ETF in Q2 2022, an estimated $25.8M increase.
  • DAFNA Capital Management's biggest Q2 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $2.3M.
  • DAFNA Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $2.17M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $367M portfolio in Q2 2022.
  • DAFNA Capital Management opened 3 new positions and closed 7 in Q2 2022.
  • DAFNA Capital Management's portfolio value fell 4.4% quarter-over-quarter to $367M.

Based on DAFNA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.